**VIVITROL (naltrexene extended release)**

Effective Date: 1/28/14  
Date Developed: 1/28/14 by Robert Sterling, MD  
Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20

Vivotrol is supplied as a microsphere formulation of naltrexone suspension, to be administered by intramuscular injection. Naltrexone is an opioid antagonist with little, if any, opioid agonist activity and blocks the effects of exogenous opioids for approximately 28 days after administration.

**Authorization:** treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting; prevention of relapse to opioid dependence, following opioid detoxification

**Dosing:** 380 mg intramuscularly every four weeks

**PRECAUTIONS:** injection site reactions; worsening depression; hypersensitivity reactions; unintended withdrawal symptoms if given prior to several days of abstinence; hepatic impairment

**DRUG INTERACTIONS:** none known

**REFERENCES**

Revision History:
Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>